Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Francesca Cibien"'
Autor:
Andrea Visentin, Francesca Romana Mauro, Gioachino Catania, Alberto Fresa, Candida Vitale, Alessandro Sanna, Veronica Mattiello, Francesca Cibien, Paolo Sportoletti, Massimo Gentile, Gian Matteo Rigolin, Francesca Maria Quaglia, Roberta Murru, Alessandro Gozzetti, Stefano Molica, Monia Marchetti, Stefano Pravato, Francesco Angotzi, Alessandro Cellini, Lydia Scarfò, Gianluigi Reda, Marta Coscia, Luca Laurenti, Paolo Ghia, Robin Foà, Antonio Cuneo, Livio Trentin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib (IB), the first-in-class BTK inhibitor, and obinutuzumab-chlorambucil
Externí odkaz:
https://doaj.org/article/26e89ef70eee4bd594a63aa05621a090
Autor:
Andrea Visentin, Vincenzo Nasillo, Monia Marchetti, Isacco Ferrarini, Rossella Paolini, Rosaria Sancetta, Gian Matteo Rigolin, Francesca Cibien, Marcello Riva, Chiara Briani, Serena Marinello, Francesco Piazza, Filippo Gherlinzoni, Mauro Krampera, Renato Bassan, Antonio Cuneo, Mario Luppi, Gianpietro Semenzato, Roberto Marasca, Livio Trentin
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e395 (2020)
Externí odkaz:
https://doaj.org/article/f0d65f3f2f0240b89034af0df445c3cb
Autor:
Andrea Visentin, Francesca Mauro, Lydia Scarfò, Massimo Gentile, Lucia Farina, Gianluigi Reda, Isacco Ferrarini, Giulia Proietti, Enrico Derenzini, Francesca Cibien, Candida Vitale, Alessandro Sanna, Gioachino Catania, Monia Marchetti, Roberta Murru, Gian Matteo Rigolin, Paolo Sportoletti, Luca Laurenti, Stefano Molica, Marta Coscia, Paolo Ghia, Robin Foa, Antonio Cuneo, Livio Trentin
Publikováno v:
Blood. 140:7045-7046
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc0279508165f88d2ca3e7a34b073f87
https://doi.org/10.1182/blood-2022-159334
https://doi.org/10.1182/blood-2022-159334
Autor:
Andrea Visentin, Francesca Romana Mauro, Francesca Cibien, Candida Vitale, Gianluigi Reda, Alberto Fresa, Stefania Ciolli, Daniela Pietrasanta, Monia Marchetti, Roberta Murru, Massimo Gentile, Gian Matteo Rigolin, Francesca Maria Quaglia, Lydia Scarfò, Paolo Sportoletti, Stefano Pravato, Francesco Piazza, Marta Coscia, Luca Laurenti, Stefano Molica, Robin Foà, Antonio Cuneo, Livio Trentin
Publikováno v:
American Journal of Hematology. 97
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57376b78db26cdb436c04954b38ebdd8
https://doi.org/10.1002/ajh.26437
https://doi.org/10.1002/ajh.26437
Autor:
Stefano Molica, Marta Coscia, Attilio Olivieri, Rosaria Sancetta, Enrico Crea, Francesca Romana Mauro, Annamaria Frustaci, Roberto Marasca, Alessandro Gozzetti, Fabrizio Pane, Francesca Cibien, Monia Marchetti, Felicetto Ferrara, Catello Califano, Lucia Farina, Luca Arcaini, Marco Montillo, Alfonso Piciocchi, Rossella Paolini, Fiorella Iliariucci, Livio Trentin, Antonio Cuneo, Paola Fazi, Omar Perbellini, Gian Matteo Rigolin, A Augello, Anna Lia Molinari, Donato Mannina, Massimo Gentile, Andrea Visentin, Caterina Patti, Annalisa Chiarenza, Gianluca Gaidano, Piero Galieni, Giulia Zamprogna, Francesca Maria Quaglia, Luca Laurenti, Daniela Pietrasanta, Roberta Murru, Paolo Sportoletti, Mauro Krampera, Marzia Varettoni, Robin Foà, Francesca Cura, Daniele Vallisa, Orsola Vitagliano
Publikováno v:
Blood. 136:23-25
Background. The PI3Kδ inhibitor idelalisib given in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) has been associated with an objective response in 81% of cases with a median PFS of 20.3 months in a phase-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1432450d6890c01103151af5bb62e8c9
https://doi.org/10.1182/blood-2020-134669
https://doi.org/10.1182/blood-2020-134669
Autor:
null Gian Matteo Rigolin, null Francesco Cavazzini, null Alfonso Piciocchi, null Valentina Arena, null Andrea Visentin, null Gianluigi Reda, null Giulia Zamprogna, null Francesca Cibien, null Orsola Vitagliano, null Marta Coscia, null Lucia Farina, null Gianluca Gaidano, null Roberta Murru, null Marzia Varettoni, null Rossella Paolini, null Paolo Sportoletti, null Daniela Pietrasanta, null Anna Lia Molinari, null Francesca M. Quaglia, null Luca Laurenti, null Roberto Marasca, null Monia Marchetti, null Francesca R. Mauro, null Enrico Crea, null Marco Vignetti, null Massimo Gentile, null Marco Montillo, null Robin Foà, null Antonio Cuneo, null GIMEMA group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71792bd138f5c161cd2b60e3d99eaa74
https://doi.org/10.1002/hon.2861/v2/response1
https://doi.org/10.1002/hon.2861/v2/response1
Autor:
Livio Trentin, Alessandro Gozzetti, Alberto Fresa, Daniela Pietrasanta, Candida Vitale, Paolo Sportoletti, Antonio Cuneo, Francesca Cibien, Gianpietro Semenzato, Robin Foà, Lydia Scarfò, Stefania Ciolli, Giovanni Pizzolo, L Laurenti, Ramona Cassin, Gianluigi Reda, Francesca Maria Quaglia, Roberta Murru, Andrea Visentin, Stefano Molica, Marta Coscia, Francesca Romana Mauro, Monia Marchetti, Gian Matteo Rigolin, Massimo Gentile
Publikováno v:
Blood. 136:30-31
INTRODUCTION. Kinase inhibitors and glycoengineered monoclonal antibody, such as obinutuzumab (G), have significantly changed the treatment landscape of chronic lymphocytic leukemia (CLL). Both like the BTK inhibitor ibrutinib (IB) and obinutuzumab p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ecf9e743af390f1d08676dbbf814558
https://doi.org/10.1182/blood-2020-136883
https://doi.org/10.1182/blood-2020-136883
Autor:
Marta Medeot, Elisabetta Calistri, Massimiliano Bonifacio, Luca Frison, Gianpietro Semenzato, Mario Tiribelli, Federico De Marchi, Filippo Gherlinzoni, Cristina Bucelli, Luigi Scaffidi, Mauro Krampera, Elena Maino, Anna Guella, Rosaria Sancetta, Francesca Cibien, Gianluca Festini, Ercole De Biasi, Achille Ambrosetti, Nicola Orofino, Giovanni Pizzolo, Claudia Minotto, Renato Fanin, Gianni Binotto, Alessandra Iurlo, Manuela Stulle
Publikováno v:
Oncotarget
Second-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients failin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270c75970be5628c761b790926aa7e0
http://hdl.handle.net/11562/977811
http://hdl.handle.net/11562/977811
Autor:
Enrico Lista, Gian Matteo Rigolin, Giulia Daghia, Antonio Cuneo, Francesca Cibien, Olga Sofritti, Roberta Gafà, Sara Martinelli, Genesio Leo, Francesco Cavazzini
Publikováno v:
International Journal of Hematology. 99:663-667
Sweet's syndrome is a rare condition with potentially disabling implications, characterized by painful skin lesions due to neutrophilic dermal infiltration and systemic inflammatory symptoms. A significant proportion of cases is malignancy associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57aa3e5a700d2b45d21f19896559b998
https://doi.org/10.1007/s12185-014-1527-9
https://doi.org/10.1007/s12185-014-1527-9
Autor:
Manuela Ferracin, Enrico Lista, Luca Formigaro, Elena Saccenti, Maurizio Cavallari, Francesco Cavazzini, Laura Lupini, Antonio Cuneo, Francesca Cibien, Cristian Bassi, Barbara Zagatti, Gian Matteo Rigolin, Maria Ciccone, Giulia Daghia, Lara Rizzotto, Olga Sofritti, Massimo Negrini, Sara Martinelli
Publikováno v:
Scopus-Elsevier
Oncotarget
Oncotarget
// Gian Matteo Rigolin 1 , Elena Saccenti 1,2 , Lara Rizzotto 1 , Manuela Ferracin 2 , Sara Martinelli 1 , Luca Formigaro 1 , Francesca Cibien 1 , Maurizio Cavallari 1 , Enrico Lista 1 , Giulia Daghia 1 , Olga Sofritti 1 , Maria Ciccone 1 , Francesco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df54ea8226a96b4cdc47ad3e5bc10dd9
http://hdl.handle.net/11392/1947615
http://hdl.handle.net/11392/1947615